This study investigates the experiences of cancer patients with neuropathy during the COVID-19 pandemic to learn how the COVID-19 pandemic affects their quality of life and clinical outcomes. This study will also explore whether there are differences between patients who received neurofeedback (NFB, a type of therapy that is thought to help normalize brain activity) and those who did not. Learning about quality of life in cancer patients with neuropathy during the COVID-19 pandemic may help guide development of programs and policies to improve chronic pain patient care and outcomes during a major global healthcare crisis.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Health-related quality of life and coronavirus disease 2019 (COVID-19)-specific domains of interest
Timeframe: through study completion, an average of 6 months
COVID-19 experiences and COVID-19 specific distress
Timeframe: through study completion, an average of 6 months
Differences in outcomes between neuropathic pain patients
Timeframe: through study completion, an average of 6 months
Coping and resilience factors
Timeframe: through study completion, an average of 6 months